Abstract:e16037 Background: Recent studies revealed chemotherapy increases anti-PD1 response of gastric cancer (GC) by reducing myeloid-derived suppressor cells (MDSCs). However, a more specific MDSC-targeted treatment is needed to further improve anti-PD1 efficacy in advanced GC. Trefoil factor family 2 (TFF2), a partial agonist of CXCR4 and a secreted anti-inflammatory peptide, can suppress MDSC expansion. Here, we developed a novel MDSC-targeted peptide TFF2-MSA and investigated whether it can synergize with anti-PD1 in syngeneic GC mouse models. Methods: Murine serum albumin (MSA) was fused to murine TFF2 to generate TFF2-MSA peptide with an extended serum half-life. ACKP (Atp4b-Cre; Cdh1-/-; LSL-KrasG12D; Trp53-/-) GC cells developed from a highly malignant diffuse GC mouse model were grafted subcutaneously into HDC-GFP transgenic mice in which the immunosuppressive histidine decarboxylase (HDC)-expressing myeloid cells were traced with GFP. These recipient mice then received either TFF2-MSA or anti-PD-1 antibody or both when tumors reached 150 mm 3 . At the endpoint, flow cytometry analysis was performed to examine immune profiles. In parallel, a group of the s.c. tumor bearing mice were followed up for survival differences in response to the treatments. In the orthotopic model, ACKP-luc cells were implanted to stomach submucosa, and recipient mice received the same treatments started after 1 week. In the metastasis model, subcutaneous flank tumors were resected in ACKP-grafted mice once tumors reached 500 mm 3 to permit spontaneous lung metastasis, and mice then received the same treatments. Results: While either TFF2-MSA or PD-1 antibody showed little benefit as a single agent (TGI 15% and 25% respectively, p>0.05), their combination dramatically suppressed ACKP s.c. tumor growth (TGI 78%, p<0.0001) and markedly prolonged median survival (64 days vs. 32.5 days in control) in a synergistic manner. The combination therapy efficiently reduced tumor HDC-GFP + MDSCs by 67%, and profoundly increased tumor-infiltrating cytotoxic CD8 + T cells by 18 fold. The myeloid/lymphoid progenitor and output ratio in the bone marrow were decreased by the combination, to a similar level of tumor-free mice. While standard chemotherapy (5-fluorouracil and oxaliplatin) showed no efficacy, adding chemotherapy to the combination further improved treatment efficacy (TGI 91%) and extended median survival to 73 days. In addition, in the orthotopic model, the TFF2-MSA/PD-1 antibody combination eradicated GC in 80% mice without recurrence compared to 0% with either monotherapy. Finally, the combination of TFF2-MSA/PD-1 antibody significantly reduced 80% lung metastasis (vs. control, p 0.05). Conclusions: Targeting MDSCs using TFF2-MSA synergizes with PD-1 blockade therapy in advanced and metastatic syngeneic mouse models of gastric cancer.

Pseudomonas Aeruginosa Mannose-Sensitive Hemagglutinin Promotes T-cell Response Via Toll-Like Receptor 4-Mediated Dendritic Cells to Slow Tumor Progression in Mice.

Therapeutic Effect of MIP-1alpha-recruited Dendritic Cells on Preestablished Solid and Metastatic Tumors.

Inhibition of EGFR pathway signaling and the metastatic potential of breast cancer cells by PA-MSHA mediated by type 1 fimbriae via a mannose-dependent manner.

PA-MSHA Inhibits Proliferation and Induces Apoptosis in Human Non-Small Cell Lung Cancer Cell Lines with Different Genotypes.

Inhibitory Effects of Pseudomonas Aeruginosa Mannose-Sensitive Hemagglutinin on Rat C6 Glioma Cell Proliferation

Pseudomonas Aeruginosa-Mannose-Sensitive Hemagglutinin Inhibits Proliferation And Induces Apoptosis In A Caspase-Dependent Manner In Human Bladder Cancer Cell Lines

PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells

Trends in Anti-Tumor Effects of Pseudomonas aeruginosa Mannose-Sensitive-Hemagglutinin (PA-MSHA): An Overview of Positive and Negative Effects

0015 PA-MSHA Inhibits Proliferation and Induces Apoptosis Through the Up-Regulation and Activation of Caspases in the Human Breast Cancer Cell Lines

Systemic Immune Response in Murine Bilateral Pheochromocytoma Model During Immunotherapy Based on a Combination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibodies (MBTA Therapy)

The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.

Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies

Neoadjuvant Pseudomonas Aeruginosa Mannose-Sensitive Hemagglutinin (PA-MSHA) and Chemotherapy Versus Placebo Plus Chemotherapy in Patients with HER2-negative Breast Cancer: a Randomized, Controlled, Double-Blind Trial

Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune‐evasion via the Toll‐like receptor 2 pathway

Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.

Effects of pseudomonas aeruginosa mannose-sensitive hemagglutination pilus strain on proliferation and invasion of post-thermotherapy hepatocellular carcinoma cells

Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery

Microwave ablation combined with PD‐L1 blockade synergistically promotes Cxcl9‐mediated antitumor immunity

The Mechanism of Pseudomonasaeruginosa Mannose Sensitive Hamemagglutination Vaccine in Inducing Apoptosis of Hepatocellular Carcinoma

Phase Ii Study of Pseudomonas Aeruginosa-Mannose-Sensitive Hemagglutinin in Combination with Capecitabine for Her-2-Negative Metastatic Breast Cancer Pretreated with Anthracycline and Taxane